| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
ADR |
| Shares
Out: |
58,240,000 |
| Market
Cap: |
931.26(M) |
| Last
Volume: |
115,349 |
Avg
Vol: |
115,030 |
| 52
Week Range: |
$9.64 - $17.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,000 |
41,000 |
370,500 |
| Total Buy Value |
$0 |
$29,000 |
$558,597 |
$1,422,084 |
| Total People Bought |
0 |
1 |
4 |
6 |
| Total Buy Transactions |
0 |
1 |
5 |
18 |
| Total Shares Sold |
0 |
75,000 |
103,975 |
103,975 |
| Total Sell Value |
$0 |
$1,089,750 |
$1,522,364 |
$1,522,364 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
2 |
2 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hatten Sandra L |
See Remarks |
• – – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
50,300 |
|
- |
|
| Thompson Phillandas T. |
See Remarks |
• – – |
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
81,000 |
|
- |
|
| Anderson Michael S |
Chief Executive Officer |
• • – |
2017-12-07 |
4 |
B |
$8.86 |
$44,295 |
D/D |
5,000 |
234,750 |
2.81 |
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-11-27 |
4 |
S |
$9.35 |
$2,377,632 |
D/D |
(254,265) |
253,413 |
|
- |
|
| Thornton Peter |
Director |
– • – |
2017-09-21 |
4 |
B |
$9.74 |
$50,215 |
D/D |
5,155 |
5,155 |
2.39 |
- |
|
| Hatten Sandra L |
See Remarks |
• – – |
2017-09-14 |
4 |
B |
$9.36 |
$19,654 |
D/D |
2,100 |
37,800 |
2.74 |
- |
|
| Thompson Phillandas T. |
See Remarks |
• – – |
2017-09-13 |
4 |
B |
$9.36 |
$46,800 |
D/D |
5,000 |
63,000 |
2.74 |
- |
|
| Hatten Sandra L |
See Remarks |
• – – |
2017-09-13 |
4 |
B |
$9.35 |
$4,673 |
D/D |
500 |
35,700 |
2.66 |
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-09-12 |
4 |
B |
$9.52 |
$190,360 |
I/I |
20,000 |
110,000 |
2.1 |
- |
|
| Divis Greg J |
See Remarks |
• – – |
2017-09-12 |
4 |
B |
$9.32 |
$98,760 |
D/D |
10,600 |
10,600 |
2.74 |
- |
|
| Anderson Michael S |
Chief Executive Officer |
• • – |
2017-09-12 |
4 |
B |
$9.80 |
$39,180 |
D/D |
4,000 |
229,750 |
2.81 |
- |
|
| Hatten Sandra L |
See Remarks |
• – – |
2017-09-12 |
4 |
B |
$9.15 |
$10,980 |
I/I |
1,200 |
3,400 |
1.99 |
- |
|
| Hatten Sandra L |
See Remarks |
• – – |
2017-09-12 |
4 |
B |
$9.19 |
$20,218 |
D/D |
2,200 |
35,200 |
2.74 |
- |
|
| Kotler Kevin |
10% Owner |
– – • |
2017-06-23 |
4 |
S |
$10.60 |
$1,706,600 |
D/D |
(161,000) |
4,133,464 |
|
- |
|
| Kotler Kevin |
10% Owner |
– – • |
2017-06-22 |
4 |
S |
$10.80 |
$1,080,000 |
D/D |
(100,000) |
4,294,464 |
|
- |
|
| Cerutti Guillaume |
Director |
– • – |
2017-06-15 |
4 |
S |
$10.46 |
$277,818 |
D/D |
(26,560) |
23,440 |
|
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-05-22 |
4 |
B |
$9.76 |
$164,944 |
I/I |
16,900 |
90,000 |
2.1 |
- |
|
| Anderson Michael S |
Chief Executive Officer |
• • – |
2017-05-19 |
4 |
B |
$10.00 |
$25,000 |
D/D |
2,500 |
225,750 |
2.81 |
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-05-19 |
4 |
B |
$9.83 |
$30,473 |
I/I |
3,100 |
73,100 |
2.1 |
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-05-18 |
4 |
B |
$9.98 |
$109,910 |
I/I |
11,013 |
70,000 |
2.1 |
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-05-17 |
4 |
A |
$9.95 |
$120,393 |
I/I |
12,100 |
58,987 |
|
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-05-16 |
4 |
A |
$10.00 |
$34,700 |
I/I |
3,470 |
46,887 |
|
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-05-15 |
4 |
A |
$10.00 |
$3,110 |
I/I |
311 |
43,417 |
|
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-05-12 |
4 |
A |
$10.00 |
$31,060 |
I/I |
3,106 |
43,106 |
|
- |
|
| Stapleton Craig R |
Director |
– • – |
2017-04-04 |
4 |
A |
$9.58 |
$143,643 |
D/D |
15,000 |
507,678 |
|
- |
|
190 Records found
|
|
Page 4 of 8 |
|
|
